Incyte

pause hold stop delay
Biotech

Incyte's $750M buyout rocked by pause on key trial, asset cull

Less than six months after closing the deal, Incyte has paused a key study over preclinical toxicology findings and axed another program altogether.
Nick Paul Taylor Nov 19, 2024 4:12am
pipeline pipes RD research

Incyte drops two PD-L1 drugs as part of 2nd pipeline clear-out

Jul 30, 2024 8:14am
Graphic image of two hands shaking with employeesexecutives on the forearms of each shaking hand

Incyte, fresh off gaining MorphoSys drug, buys Escient for $750M

Apr 23, 2024 10:43am
An arrow incrementally going up stairs before pointing straight up Blue background

Incyte's oral Dupixent rival hits in midphase skin disease trial

Mar 11, 2024 7:16am
merger MA unit combine consolidate deal

Novartis will pay €2.7B to pick up cancer specialist MorphoSys

Feb 5, 2024 7:06pm
research test tube pipette laboratory clinical trial study science

Agilent, Incyte ink hematology, oncology companion testing deal

Jan 30, 2024 12:28pm